ethyl N-(2-methyl-3-nitrophenyl)-acetimidate | 133053-71-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl N-(2-methyl-3-nitrophenyl)-acetimidate
• 英文别名: N-(2-methyl-3-nitro-phenyl)-acetimidic acid ethyl ester；Ethyl N-(2-methyl-3-nitrophenyl)acetimidate；ethyl N-(2-methyl-3-nitrophenyl)ethanimidate
• CAS: 133053-71-1
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: LJBZXGOXRIGJJE-UHFFFAOYSA-N

物化性质

• 沸点：
  330.5±52.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl N-(2-methyl-3-nitrophenyl)-acetimidate 在 potassium ethoxide 、 草酸二乙酯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 以27%的产率得到2-甲基-4-硝基吲哚
  参考文献：
  名称：

  通过2-烷基硝基苯胺衍生物的闭环合成吲哚

  摘要：

  由草酸二烷基酯促进的碱诱导的环化反应，由2-烷基-3-或5-硝基苯胺的亚氨酸酯，am和仲-苯胺衍生物制备了多种硝基吲哚。结果表明，在一个简单的操作中，基本上相同的方法也可用于合成相应的硝基吲哚-3-乙醛酸酯。讨论了合成潜力，并提出了一种机理。

  DOI：

  10.1016/s0040-4020(01)87932-1
• 作为产物：
  描述：

  2-甲基-3-硝基苯胺 、 原乙酸三乙酯 在 对甲苯磺酸 作用下， 反应 1.0h， 以73%的产率得到ethyl N-(2-methyl-3-nitrophenyl)-acetimidate
  参考文献：
  名称：

  通过2-烷基硝基苯胺衍生物的闭环合成吲哚

  摘要：

  由草酸二烷基酯促进的碱诱导的环化反应，由2-烷基-3-或5-硝基苯胺的亚氨酸酯，am和仲-苯胺衍生物制备了多种硝基吲哚。结果表明，在一个简单的操作中，基本上相同的方法也可用于合成相应的硝基吲哚-3-乙醛酸酯。讨论了合成潜力，并提出了一种机理。

  DOI：

  10.1016/s0040-4020(01)87932-1

文献信息

• NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF
  申请人：Sanwa Kagaku Kenkyusho Co., Ltd

  公开号：EP2036887A1

  公开（公告）日：2009-03-18

  An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

  本发明的目的是提供一种药物，作为甲状腺激素受体配体，其在药物疗效和安全性上足够，并且具有作为药物的优秀作用。本发明提供了一种由以下通式（I）表示的化合物或其药用可接受的盐：[其中[化学公式2]是单键或双键；A是-CH2-或-CO-；X、Y和Z各自独立为氮原子或碳原子；R1是氢原子或芳烷基团；R2是烷基团或芳烷基团等；R3是氢原子或烷基团等；R4是氢原子或烷基团；R5是氢原子、烷基团或卤素低烷基团等；R6是氢原子或烷基团；R7是氢原子等；R8是氢原子或烷基团等；E是-NHCO-G-COR12等（其中G是单键或亚烷基团，R12是羟基或烷氧基）]。
• NOVEL 6-5 SYSTEM BICYCLIC HETEROCYCLIC DERIVATIVE AND ITS PHARMACEUTICAL UTILITY
  申请人：Asano Yukiyasu

  公开号：US20090176841A1

  公开（公告）日：2009-07-09

  An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is —CH 2 — or —CO—; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R 1 is a hydrogen atom or an aralkyl group; R 2 is an alkyl group or an aralkyl group, etc.; R 3 is a hydrogen atom or an alkyl group, etc.; R 4 is a hydrogen atom or an alkyl group; R 5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R 6 is a hydrogen atom or an alkyl group; R 7 is a hydrogen atom, etc.; R 8 is a hydrogen atom, or an alkyl group, etc.; and E is —NHCO-G-COR 12 , etc. (wherein G is a single bond or an alkylene group, and R 12 is a hydroxy group or an alkoxy group)].

  本发明的目的是提供一种作为甲状腺激素受体配体的药物，具有充分的药效和安全性，并具有优秀的药物作用。本发明提供了以下通式（I）所表示的化合物或其药学上可接受的盐：[其中[化学式2]是单键或双键；A是-CH2-或-CO-；X、Y和Z分别是氮原子或碳原子；R1是氢原子或芳基烷基；R2是烷基或芳基烷基等；R3是氢原子或烷基等；R4是氢原子或烷基；R5是氢原子、烷基或卤代低烷基等；R6是氢原子或烷基；R7是氢原子等；R8是氢原子或烷基等；E是-NHCO-G-COR12等（其中G是单键或烷基亚基，R12是羟基或烷氧基）]。
• Synthesis, in vitro and in vivo preliminary evaluation of anti-angiogenic properties of some pyrroloazaflavones
  作者：Maria Grazia Ferlin、Maria Teresa Conconi、Luca Urbani、Barbara Oselladore、Diego Guidolin、Rosa Di Liddo、Pier Paolo Parnigotto

  DOI：10.1016/j.bmc.2010.11.010

  日期：2011.1

  This work investigated the in vitro and in vivo anti-angiogenic activity of some pyrroloazaflavones, exactly 2-phenyl-1H-pyrrolo[2,3-h]quinolin-4(7H) ones, with vinblastine as reference compound. Growth inhibitory activity, migration, and capillary-like structures formation were determined in human umbilical vein endothelial cell cultures, and Matrigel plug assay was carried out to evaluate in vivo effects on angiogenesis. Collectively, our results indicate that some pyrroloazaflavone derivatives, at non-cytotoxic concentrations and like vinblastine are able: (i) to exert in vitro anti-angiogenic activity and (ii) to counteract in vitro and in vivo the pro-angiogenic effects of fibroblast growth factor-2 (FGF-2). (C) 2010 Elsevier Ltd. All rights reserved.
• Synthesis of indoles via ring closure of 2-alkylnitroaniline derivatives
  作者：Jan Bergman、Peter Sand

  DOI：10.1016/s0040-4020(01)87932-1

  日期：1990.1

  A variety of nitroindoles have been prepared from imidate, amidine, and sec-anilide derivatives of 2-alkyl-3- or 5-nitroanilines by a base-induced cyclization promoted by dialkyl oxalates. It is shown that essentially the same procedure also can be used to synthesize the corresponding nitroindole-3-glyoxylates in one simple operation. The synthetic potential is discussed and a mechanism is proposed

  由草酸二烷基酯促进的碱诱导的环化反应，由2-烷基-3-或5-硝基苯胺的亚氨酸酯，am和仲-苯胺衍生物制备了多种硝基吲哚。结果表明，在一个简单的操作中，基本上相同的方法也可用于合成相应的硝基吲哚-3-乙醛酸酯。讨论了合成潜力，并提出了一种机理。